GYNISUS

Company Overview

Snapshot

Founded in January 2017 by Hila Friedmann, Zoya Gordon, and Israel Meizner, GYNISUS operates with 11–50 employees. The company has raised $50,000 across three funding rounds. In March 2023, GYNISUS secured seed funding from Plug and Play.

Business overview

GYNISUS is a Health Tech & Life Sciences company that leverages artificial intelligence to enhance diagnosis and treatment processes. Its core offering, the SPAI platform, delivers intelligent insights and predictions for the healthcare sector. The company's solutions, including the Infectious Disease Intelligence Platform, are designed to assist hospitals, home nursing facilities, and senior living centers in identifying individuals at higher risk for complications and disease, as well as improving resource utilization and cost management. GYNISUS operates in the Digital Healthcare, Digital Medical Diagnostics, and Medical Decision Support sectors, serving geomarkets such as the United States, Israel, Europe, India, and Brazil.

Company Intelligence Q&A

What is the primary focus of GYNISUS's technology?

GYNISUS utilizes artificial intelligence through its SPAI platform to provide intelligent insights and predictions for the healthcare space, aiming to improve diagnosis and treatment.

What is the status of GYNISUS?

GYNISUS is currently Non Active and ceased to operate in August 2024.

When was GYNISUS founded and by whom?

GYNISUS was founded in January 2017 by co-founders Hila Friedmann, Zoya Gordon, and Israel Meizner.

What was a key funding event for GYNISUS?

The round was led by Plug and Play.

Which markets does GYNISUS serve?

GYNISUS targets geomarkets including the United States, Israel, Europe, India, and Brazil.